U.S. markets closed
  • S&P Futures

    4,088.00
    +6.75 (+0.17%)
     
  • Dow Futures

    34,593.00
    -6.00 (-0.02%)
     
  • Nasdaq Futures

    12,064.25
    +22.00 (+0.18%)
     
  • Russell 2000 Futures

    1,893.40
    +5.90 (+0.31%)
     
  • Crude Oil

    80.56
    +0.01 (+0.01%)
     
  • Gold

    1,793.10
    +33.20 (+1.89%)
     
  • Silver

    22.57
    +0.79 (+3.62%)
     
  • EUR/USD

    1.0444
    +0.0036 (+0.34%)
     
  • 10-Yr Bond

    3.7030
    -0.0450 (-1.20%)
     
  • Vix

    20.58
    -1.31 (-5.98%)
     
  • GBP/USD

    1.2103
    +0.0041 (+0.34%)
     
  • USD/JPY

    136.5970
    -1.4830 (-1.07%)
     
  • BTC-USD

    17,139.86
    +264.66 (+1.57%)
     
  • CMC Crypto 200

    406.48
    +5.79 (+1.44%)
     
  • FTSE 100

    7,573.05
    +61.05 (+0.81%)
     
  • Nikkei 225

    28,302.35
    +333.36 (+1.19%)
     

Glaukos Shares Pop After Positive Data From Ocular Pressure Candidate

  • Glaukos Corporation (NASDAQ: GKOSannounced positive topline data for both Phase 3 trials of iDose TR. It achieved its pre-specified primary efficacy endpoints through 3 months and demonstrated excellent tolerability and a favorable safety profile through 12 months.

  • The fast- and slow-release iDose TR arms achieved the primary efficacy endpoint of non-inferiority to the active comparator arm (topical timolol ophthalmic solution).

  • Related: Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment.

  • For the GC-010 trial, the intraocular pressure (IOP) reductions from baseline were 6.6-8.5 mmHg in the slow-release iDose TR arm versus 6.6-7.7 mmHg in the timolol control arm.

  • For the GC-012 trial, IOP reductions were 6.7-8.4 mmHg in the slow-release iDose TR arm versus 6.8-7.2 mmHg in the timolol control arm.

  • 93% of slow-release iDose TR subjects remained well-controlled on the same or fewer IOP-lowering topical medications at 12 months compared to screening after a single administration of iDose TR, versus 67% of timolol control subjects.

  • Additionally, 81% of slow-release iDose TR subjects were completely free of IOP-lowering topical medications.

  • iDose TR demonstrated a favorable safety profile.

  • Glaukos plans to move forward with its plans for marketing application submission to the FDA for the slow-release iDose TR model, with an expected FDA review and decision completed by the end of 2023.

  • Price Action: GKOS shares are up 16.80% at $56.16 on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.